(Q61911235)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8471331%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

title

Combination of interleukin-2 and gamma interferon in metastatic renal cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8471331%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

0 references

1 reference

metastatic renal cell carcinoma

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8471331%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

author name string

B Escudier

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8471331%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

F Farace

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8471331%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

F Triebel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8471331%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

S Antoun

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8471331%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

B Leclercq

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8471331%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

M Brandely

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8471331%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

A Aboudaram

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8471331%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

G Nitenberg

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8471331%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

T Hercend

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8471331%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

publication date

1 January 1993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8471331%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

13 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8471331%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

volume

29A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8471331%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8471331%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

page(s)

724-728

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8471331%20AND%20SRC:MED&resulttype=core&format=json

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

13 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980354-5

7 January 2021

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980354-5

7 January 2021

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980354-5

7 January 2021

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980354-5

7 January 2021

Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980354-5

7 January 2021

Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980354-5

7 January 2021

Phase II study of interferon alfa-2a, recombinant (Roferon-A) in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980354-5

7 January 2021

Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980354-5

7 January 2021

Combination of recombinant interferon alpha-2a and vinblastine in advanced renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980354-5

7 January 2021

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980354-5

7 January 2021

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980354-5

7 January 2021

Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980354-5

7 January 2021

Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980354-5

7 January 2021

Adoptive immunotherapy of murine pulmonary metastases with interleukin 2 and interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980354-5

7 January 2021

Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980354-5

7 January 2021

A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980354-5

7 January 2021

Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980354-5

7 January 2021

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980354-5

7 January 2021

Acute renal failure during therapy with recombinant human gamma interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980354-5

7 January 2021

A case of fatal pemphigus vulgaris in association with beta interferon and interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2805%2980354-5

7 January 2021

10.1016/S0959-8049(05)80354-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8471331%20AND%20SRC:MED&resulttype=core&format=json

13 October 2019

1 reference